Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Vigneswaran, Nadarajah ^a   Baucum, Darryl C ^a   Wu, Jean ^a   Lou, Yahuan ^a   Bouquot, Jerry ^a   Muller, Susan ^b   Zacharias, Wolfgang ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; DNA MICROARRAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; LYMPH NODE METASTASIS; MALE; MOUTH CARCINOMA; MOUTH MUCOSA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; CASE CONTROL STUDY; CELL CULTURE; CELL DEATH; CELL TRANSFORMATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MOUTH TUMOR; NEEDLE BIOPSY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL DEATH; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; PROGNOSIS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED;

EID: 34547451794     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-108     Document Type: Article

References (59)

1. Kemp TJ Kim JS Crist SA Griffith TS Induction of necrotic tumor cell death by TRAIL/Apo-2L Apoptosis 2003 8 6 587-599 10.1023/A:1026286108366 14739604
2. Wajant H Pfizenmaier K Scheurich P TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy Apoptosis 2002 7 5 449-459 10.1023/A:1020039225764 12207178
3. Ashkenazi A Targeting death and decoy receptors of the tumour-necrosis factor superfamily Nat Rev Cancer 2002 2 6 420-430 10.1038/nrc821 12189384
4. Yagita H Takeda K Hayakawa Y Smyth MJ Okumura K TRAIL and its receptors as targets for cancer therapy Cancer Sci 2004 95 10 777-783 10.1111/ j.1349-7006.2004.tb02181.x 15504243
5. Griffith TS Lynch DH TRAIL: A molecule with multiple receptors and control mechanisms Curr Opin Immunol 1998 10 5 559-563 10.1016/ S0952-7915(98)80224-0 9794836
6. Sheridan JP Marsters SA Pitti RM Gurney A Skubatch M Baldwin D Ramakrishnan L Gray CL Baker K Wood WI Goddard AD Godowski P Ashkenazi A Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors Science 1997 277 5327 818-821 10.1126/science.277.5327.818 9242611
7. Vigneswaran N Wu J Nagaraj N Adler-Storthz K Zacharias W Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis Int J Oncol 2005 26 1 103-112 15586230
8. Zhang L Fang B Mechanisms of resistance to TRAIL-induced apoptosis in cancer Cancer Gene Ther 2005 12 3 228-237 10.1038/sj.cgt.7700792 15550937
9. Mace TA Yamane N Cheng J Hylander BL Repasky EA The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis Immunol Invest 2006 35 3-4 279-296 10.1080/08820130600745463 16916755
10. Nagaraj NS Vigneswaran N Zacharias W Hypoxia inhibits TRAIL-induced tumor cell apoptosis: Involvement of lysosomal cathepsins Apoptosis 2007 12 1 125-139 10.1007/s10495-006-0490-1 17136492
11. Ashkenazi A Pai RC Fong S Leung S Lawrence DA Marsters SA Blackie C Chang L McMurtrey AE Hebert A DeForge L Koumenis IL Lewis D Harris L Bussiere J Koeppen H Shahrokh Z Schwall RH Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 1999 104 2 155-162 408479 10411544
12. Walczak H Miller RE Ariail K Gliniak B Griffith TS Kubin M Chin W Jones J Woodward A Le T Smith C Smolak P Goodwin RG Rauch CT Schuh JC Lynch DH Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med 1999 5 2 157-163 10.1038/5517 9930862
13. Chinnaiyan AM Prasad U Shankar S Hamstra DA Shanaiah M Chenevert TL Ross BD Rehemtulla A Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy Proc Natl Acad Sci U S A 2000 97 4 1754-1759 26508 10677530 10.1073/pnas.030545097
14. Gliniak B Le T Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11 Cancer Res 1999 59 24 6153-6158 10626806
15. Marini P Schmid A Jendrossek V Faltin H Daniel PT Budach W Belka C Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis BMC Cancer 2005 5 5 547906 15651986 10.1186/ 1471-2407-5-5
16. Marini P Denzinger S Schiller D Kauder S Welz S Humphreys R Daniel PT Jendrossek V Budach W Belka C Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Enhanced effects in vitro and dose-dependent growth delay in vivo Oncogene 2006 25 37 5145-5154 16636678
17. Pukac L Kanakaraj P Humphreys R Alderson R Bloom M Sung C Riccobene T Johnson R Fiscella M Mahoney A Carrell J Boyd E Yao XT Zhang L Zhong L von Kerczek A Shepard L Vaughan T Edwards B Dobson C Salcedo T Albert V HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo Br J Cancer 2005 92 8 1430-1441 10.1038/sj.bjc.6602487 15846298
18. Shankar S Srivastava RK Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: Mechanisms and clinical implications Drug Resist Updat 2004 7 2 139-156 10.1016/ j.drup.2004.03.002 15158769
19. Finnberg N El-Deiry WS Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies Clin Cancer Res 2006 12 14 Pt 1 4132-4136 10.1158/1078-0432.CCR-06-0567 16857782
20. Anonymous Human Genome Sciences Completes Patient Enrollment in A Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Non-Small Cell Lung Cancer 2005 http://www.prnewswire.com/cgi-bin/stories.pl?ACCT= 104&STORY=/www/story/11-30-2004/0002554615&EDATE=
21. Takeda K Hayakawa Y Smyth MJ Kayagaki N Yamaguchi N Kakuta S Iwakura Y Yagita H Okumura K Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells Nat Med 2001 7 1 94-100 10.1038/83416 11135622
22. Seki N Hayakawa Y Brooks AD Wine J Wiltrout RH Yagita H Tanner JE Smyth MJ Sayers TJ Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer Cancer Res 2003 63 1 207-213 12517799
23. Rowinsky EK Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents J Clin Oncol 2005 23 36 9394-9407 10.1200/ JCO.2005.02.2889 16361639
24. Fukuda M Hamao A Tanaka A Kitada M Suzuki S Kusama K Sakashita H Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity Oncol Rep 2003 10 5 1113-1119 12883666
25. Teng MS Brandwein-Gensler MS Teixeira MS Martignetti JA Duffey DC A study of TRAIL receptors in squamous cell carcinoma of the head and neck Arch Otolaryngol Head Neck Surg 2005 131 5 407-412 10.1001/ archotol.131.5.407 15897419
26. Sacks PG Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck Cancer Metastasis Rev 1996 15 1 27-51 10.1007/BF00049486 8842478
27. Vigneswaran N Beckers S Waigel S Mensah J Wu J Mo J Fleisher KE Bouquot J Sacks PG Zacharias W Increased EMMPRIN (CD 147) expression during oral carcinogenesis Exp Mol Pathol 2006 80 2 147-159 10.1016/ j.yexmp.2005.09.011 16310185
28. Vigneswaran N Wu J Sacks P Gilcrease M Zacharias W Microarray gene expression profiling of cell lines from primary and metastatic tongue squamous cell carcinoma: Possible insights from emerging technology J Oral Pathol Med 2005 34 2 77-86 10.1111/j.1600-0714.2004.00258.x 15641986
29. Park NH Gujuluva CN Baek JH Cherrick HM Shin KH Min BM Combined oral carcinogenicity of HPV-16 and benzo(a)pyrene: An in vitro multistep carcinogenesis model Oncogene 1995 10 11 2145-2153 7784058
30. Pindborg JJ Reichart PA Smith CJ der. WJ Histological Typing of Cancer and Precancer of the Oral Mucosa WHO New York, Springer 2nd 1997 9146862
31. Gown AM Willingham MC Improved detection of apoptotic cells in archival paraffin sections: Immunohistochemistry using antibodies to cleaved caspase 3 J Histochem Cytochem 2002 50 4 449-454 11897797
32. Vigneswaran N Zhao W Dassanayake A Muller S Miller DM Zacharias W Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer Hum Pathol 2000 31 8 931-937 10.1053/hupa.2000.9035 10987253
33. Nagaraj NS Vigneswaran N Zacharias W Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells J Cancer Res Clin Oncol 2006 132 3 171-183 10.1007/s00432-005-0053-9 16362335
34. Jalving M de Jong S Koornstra JJ Boersma-van Ek W Zwart N Wesseling J de Vries EG Kleibeuker JH TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas Clin Cancer Res 2006 12 14 Pt 1 4350-4356 10.1158/1078-0432.CCR-05-2487 16857810
35. Lu X Arbiser JL West J Hoedt-Miller M Sheridan A Govindarajan B Harral JW Rodman DM Fouty B Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalignant cells Am J Pathol 2004 165 5 1613-1620 1618658 15509531
36. Popnikolov NK Gatalica Z Adegboyega PA Norris BA Pasricha PJ Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma Appl Immunohistochem Mol Morphol 2006 14 2 161-165 10.1097/ 01.pai.0000157905.30872.9f 16785783
37. Stander S Schwarz T Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer Am J Dermatopathol 2005 27 2 116-121 10.1097/ 01.dad.0000154401.45465.ee 15798435
38. Strater J Hinz U Walczak H Mechtersheimer G Koretz K Herfarth C Moller P Lehnert T Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter Clin Cancer Res 2002 8 12 3734-3740 12473583
39. Xu J Zhou JY Wu GS Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy Cancer Res 2006 66 20 10092-10099 10.1158/0008-5472.CAN-06-1633 17047073
40. Clarke N Jimenez-Lara AM Voltz E Gronemeyer H Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL Embo J 2004 23 15 3051-3060 514919 15241475 10.1038/ sj.emboj.7600302
41. Wang Q Wang X Hernandez A Hellmich MR Gatalica Z Evers BM Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells J Biol Chem 2002 277 39 36602-36610 10.1074/ jbc.M206306200 12140294
42. Kalyankrishna S Grandis JR Epidermal growth factor receptor biology in head and neck cancer J Clin Oncol 2006 24 17 2666-2672 10.1200/ JCO.2005.04.8306 16763281
43. Lazarus P Sheikh SN Ren Q Schantz SP Stern JC Richie JP Jr. Park JY p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use Carcinogenesis 1998 19 3 509-514 10.1093/carcin/19.3.509 9525287
44. El-Deiry WS Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling Cell Death Differ 2001 8 11 1066-1075 10.1038/ sj.cdd.4400943 11687885
45. Winn DM Epidemiology of cancer and other systemic effects associated with the use of smokeless tobacco Adv Dent Res 1997 11 3 313-321 9524431
46. Koornstra JJ Kleibeuker JH van Geelen CM Rijcken FE Hollema H de Vries EG de Jong S Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas J Pathol 2003 200 3 327-335 10.1002/path.1364 12845629
47. McCarthy MM DiVito KA Sznol M Kovacs D Halaban R Berger AJ Flaherty KT Camp RL Lazova R Rimm DL Kluger HM Expression of tumor necrosis factor - related apoptosis-inducing ligand receptors 1 and 2 in melanoma Clin Cancer Res 2006 12 12 3856-3863 1839847 16778114 10.1158/ 1078-0432.CCR-06-0190
48. McCarthy MM Sznol M DiVito KA Camp RL Rimm DL Kluger HM Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer Clin Cancer Res 2005 11 14 5188-5194 10.1158/ 1078-0432.CCR-05-0158 16033835
49. Shivapurkar N Toyooka S Toyooka KO Reddy J Miyajima K Suzuki M Shigematsu H Takahashi T Parikh G Pass HI Chaudhary PM Gazdar AF Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types Int J Cancer 2004 109 5 786-792 10.1002/ijc.20041 14999791
50. Spierings DC de Vries EG Timens W Groen HJ Boezen HM de Jong S Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors Clin Cancer Res 2003 9 9 3397-3405 12960128
51. Sheikh MS Burns TF Huang Y Wu GS Amundson S Brooks KS Fornace AJ Jr. el-Deiry WS p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha Cancer Res 1998 58 8 1593-1598 9563466
52. Ravi R Bedi GC Engstrom LW Zeng Q Mookerjee B Gelinas C Fuchs EJ Bedi A Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB Nat Cell Biol 2001 3 4 409-416 10.1038/35070096 11283615
53. Frey AB Monu N Effector-phase tolerance: Another mechanism of how cancer escapes antitumor immune response J Leukoc Biol 2006 79 4 652-662 10.1189/jlb.1105628 16415165
54. Reichert TE Strauss L Wagner EM Gooding W Whiteside TL Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma Clin Cancer Res 2002 8 10 3137-3145 12374681
55. Koyama S Differential expression of intracellular apoptotic signaling molecules in tumor and tumor-infiltrating lymphocytes during development of invasion and/or metastasis of gastric carcinoma Dig Dis Sci 2003 48 12 2290-2300 10.1023/B:DDAS.0000007865.96569.9a 14714615
56. Barnes L Ferlito A Altavilla G MacMillan C Rinaldo A Doglioni C Basaloid squamous cell carcinoma of the head and neck: Clinicopathological features and differential diagnosis Ann Otol Rhinol Laryngol 1996 105 1 75-82 8546432
57. Altavilla G Mannara GM Rinaldo A Ferlito A Basaloid squamous cell carcinoma of oral cavity and oropharynx ORL J Otorhinolaryngol Relat Spec 1999 61 3 169-173 10325559
58. O'Connell J O'Sullivan GC Collins JK Shanahan F The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand J Exp Med 1996 184 3 1075-1082 10.1084/jem.184.3.1075 9064324
59. Koyama S Koike N Adachi S Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: A possible mechanism of immune evasion of the tumor J Cancer Res Clin Oncol 2002 128 2 73-79 10.1007/ s004320100292 11862476